ANI Pharmaceuticals, Inc.ANIPNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Trending lower, below historical average, strong compound growth.
Left:
||||
Year-over-year research & development expense growth
Latest
30.03%
↓ 33% below average
Average (9y)
45.07%
Historical baseline
Range
High:212.11%
Low:-28.95%
CAGR
+17.0%
Consistent expansion
| Period | Value |
|---|---|
| 2024 | 30.03% |
| 2023 | 53.62% |
| 2022 | 96.31% |
| 2021 | -28.95% |
| 2020 | -19.21% |
| 2019 | 28.71% |
| 2018 | 69.66% |
| 2017 | 212.11% |
| 2016 | 1.11% |
| 2015 | 7.32% |